Shares of Bellerophon Therapeutics, Inc. (BLPH) are rising more than 25% at $2.39.
The company today announced into a subscription agreement with a life sciences-focused institutional investor to sell 718,474 shares at a price of $2.00 per share and 1,781,526 prefunded warrants at $1.99 per pre-funded warrant.
The company intends to use the proceeds of about$5 million from this offering to complete its Phase 3 REBUILD study of inhaled nitric oxide (iNO) in patients at risk for pulmonary hypertension, and for working capital and general corporate purposes.
The offering is expected to close on March 7.
BLPH has traded in the range of $0.67-$3.50 in the last 1 year.
Source: Read Full Article
Lates News:
-
K33 Research Highlights Unwavering Institutional Demand for Bitcoin
-
Palo Alto Networks Shares Rise On Improved Q4 Results, Outlook
-
Over 70% of Bitcoin's Circulating Supply Held by Long-Term Holders — What This Means For BTC
-
MicroStrategy Adds To Bitcoin Stash, Now Holds $4.6 Billion
-
Bloomberg Expert Analyst Explains Why A Fall To $10,000 Isn’t Bad For Bitcoin